Abstract 6240: A phase 1 study of selective PI3Kγ inhibitor ZX-4081 in patients with advanced solid tumors
Year: 2022
Type: conference-abstract
Source: Cancer Research
Authors: Xiaoli Qin, Edgar Bautista, Ying-ying Li, Xiaomin Li, Zhiyuan Peng, Deming Kong, Jinfu Yang, Xiaolin Hao
Institution: Nanjing Zenshine Pharmaceuticals Co., Ltd. (China)
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: PI3Kγ inhibitor, advanced solid tumors, myeloid cell activation, tumor microenvironment, CD8+ T cells, M1-like macrophages, immune checkpoint inhibitor resistance, antitumor immunity, 4T1 breast cancer, CT26 cells, pharmacokinetics, pharmacodynamics, safety and tolerability, dose escalation
Open Access status: closed
OpenAlex ID: W4282968097
